newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that